Organon (OGN) said Wednesday it has agreed to acquire Roivant's (ROIV) Dermavant, including its flagship dermatological cream Vtama, for a total consideration of $1.2 billion.
Under the deal, Organon will pay $175 million upfront with $75 million as milestone payment after the US Food and Drug Administration approves Vtama's application for treatment of atopic dermatitis, followed by commercial milestone payments of up to $950 million. The companies expect the FDA to decide on its review in Q4.
The transaction is expected to close in Q4.
Price: 20.22, Change: -0.33, Percent Change: -1.61
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.